olysio
Janssen sales follow J&J’s downward trend
July 15, 2015Sales and Marketing J&J, JJ, Johnson & Johnson, Johnson and Johnson, financial results, olysio
Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Janssen privy to new pricing scheme and see NICE nod
January 16, 2015Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir
Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …
New drugs see J&J sales rise
July 17, 2014Medical Communications, Sales and Marketing J&J, JJ, Q2, hepatitis C, olysio, sovaldi
Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance …
J&J profits up amid drug gains
January 23, 2014Sales and Marketing FDA, J&J, JJ, Remicade, Zytiga, olysio, q4
Johnson & Johnson’s sales in the fourth quarter of 2013 rose 4.5% compared to the same period in the previous …
FDA approves Olysio
November 25, 2013Sales and Marketing FDA, Janseen, Janssen, hep C, hepc, olysio, simeprevir
US regulators have approved Janssen Pharmaceuticals’ Olysio, a new therapy to treat chronic hepatitis C virus infection, after a priority …
